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variety of settings, including high prevalence.
Editor: Patrik Bavoil
ABSTRACT
Serological assays can be used to investigate the population burden of infection and potentially sequelae from Chlamydia.
We investigated the PGP3 ELISA as a sero-epidemiological tool for infection or sub-fertility in Australian and Samoan
women. The PGP3 ELISA absorbance levels were compared between groups of women with infertility, fertile, and current
chlamydial infections. In the Australian groups, women with chlamydial tubal factor infertility had significantly higher
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absorbance levels in the PGP3 ELISA compared to fertile women (P < 0.0001), but not when compared to women with
current chlamydial infection (P = 0.44). In the Samoan study, where the prevalence of chlamydial infections is much higher
there were significant differences in the PGP3 ELISA absorbance levels between chlamydial sub-fertile women and fertile
women (P = 0.003). There was no difference between chlamydial sub-fertile women and women with a current infection
(P = 0.829). The results support that the PGP3 assay is effective for sero-epidemiological analysis of burden of infection, but
not for evaluation of chlamydial pathological sequelae such as infertility.
Keywords: chlamydia; ELISA; Sero-epidemiology; serology; Sub-fertility; tubal factor infertility
INTRODUCTION
Chlamydia trachomatis is the most common bacterial sexually
transmitted infectionworldwide. Infections can result in serious
sequelae such as pelvic inflammatory disease, tubal factor infer-
tility (TFI) and ectopic pregnancy (reviewed (Menon et al. 2015)).
Estimating the population attributable risk of these sequelae is
difficult as they havemultiple aetiologies and are often not diag-
nosed until sometime after infection (Menon et al. 2015). Serolog-
ical assays have the potential to be used in population studies to
estimate the burden of sequelae attributable to chlamydia, and
to evaluate and monitor health interventions.
Ades et al. 2017 evaluated whole organism immunofluores-
cence titres (WIF) across a 10-year period, for women undergo-
ing care for tubal factor infertility (Ades et al. 2017). Titres were
analysed using a finitemixturemodels approach to estimate the
population excess fraction of chlamydial TFI (case-control study
of TFI compared with female infertility from other causes) to be
28% (95% credible interval [CrI]: 5%–95%) andmaximum of 46.8%
(95% CrI: 23.3%–64.1%) (Ades et al. 2017). The population burden
beyond the infertility setting remains less well characterised,
and relatively few sero-epidemiological studies have included
fertile women as controls (Menon et al. 2016a).
Numerous studies have shown that chlamydial sero-
positivity, in infertile women has been significantly associated
with laparoscopically diagnosed TFI (Gijsen et al. 2002; Akande
et al. 2003; Land et al. 2010). However, the sensitivity and speci-
ficity of the assays used vary considerably. Recent studies in
the UK have demonstrated that the Pgp3 ELISA (enzyme linked
immunosorbent assay) (Wills et al. 2009; Horner et al. 2016) could
be used for such monitoring and evaluating (Horner et al. 2013;
Horner et al. 2016; Woodhall et al. 2017). Here, we explored the
Pgp3 ELISA as a surveillance assay in women from Australia
and Samoa who have infertility/sub-fertility, fertility or current
infection (Huston et al. 2010;Walsh et al. 2015; Menon et al. 2016a;
Menon et al. 2016b).
MATERIALS AND METHODS
Study design and participant groups
The study aimed to evaluate if the PGP3 ELISA could be used
for estimating the burdens of chlamydial infertility and/or infec-
tion in women fromAustralia and Samoa.We tested absorbance
levels in the PGP3 ELISA using a 1/100 serum dilution, from
previously described samples (Huston et al. 2010; Walsh et al.
2015; Menon et al. 2016a; Menon et al. 2016b). Participants from
Australia (n = 302) were categorised into four groups. Group 1
was infertile women with greater than a year of trying to con-
ceive, who all had laparoscopic investigations for tubal occlu-
sion (Menon et al. 2016a). Past chlamydial infection measured
by MIF was used to define chlamydial TFI. Group 2 were fertile
women attending antenatal care, who had never had assisted
reproductive technologies and whose current pregnancy took
less than 1 year to conceive (Menon et al. 2016a). Group 3 were
women attending University General Practice or Sexual Health
Clinics with a NAAT confirmed chlamydial infection (Huston
et al. 2010; Menon et al. 2016a) (serum was typically collected
when participants returned for treatment, within 1week). Group
4 was a separate group of infertile women, in this group chlamy-
dial sero-positivity (MIF) and tubal factor infertility diagnosis
were used to define chlamydial TFI (Menon et al. 2016a). Group 5
(n = 239) were from a previously described study in Samoa (high
chlamydia prevalence) where urine for PCR and blood for serum
was collected at the same time (Walsh et al. 2015; Menon et al.
2016b). The serological results from Samoan women were anal-
ysed using two groupings (Table 1). First, based on epidemiolog-
ical data, and previous serological results (MIF), they were cat-
egorised into chlamydial sub-fertile or fertile. The second anal-
ysis was by grouping the participants from Samoa into women
who had a infection confirmed by NAAT compared to currently
NAAT negative women.
ELISA Protocol and analysis
PGP3 ELISA was conducted as previously described (Wills et al.
2009), with the exception that the blocking agent was skimmilk
powder (0.5%). Samples were re-tested or excluded when the
standard error deviated by more than 5% within the replicates
(mean of replicates were analysed). All analysis was conducted
in IBM SPSS V 25.
Ethics statement
The study was reviewed by Human Research Ethics Commit-
tees and each participant provided informed written consent.
Human Research Committee Ethical Approvals include: Monash
Private Surgical Human Research Ethics Committee (HREC)
(12 099); UC Health HREC (1221); Prince Charles Hospital HREC
(EC2809); Ipswich and West Moreton Health Services District
HREC (10-09), Gold Coast Hospital District HREC (200 893); Cairns
Sexual Health HREC (09/QCH/4–554); Queensland University of
Technology HREC (080000268); and University of Technology
Sydney HREC (2015000699), and initial ethical approval was from
National University of Samoa, Samoa National Health Service
Board approval for the use of the Laboratory and staff, and the
Samoa Ministry of Women approved the village based survey,
and the Samoan Ministry of Health.
RESULTS
The PGP3 ELISA absorbance level was significantly higher when
chlamydia infertile (or sub-fertile) women were compared with
women who were infertile (or sub-fertile) for other reasons
(n = 11, n = 86 respectively, Group 1: P < 0.0001) in only one of
two groups in Australia (Table 1). Women who were categorized
as chlamydia sub-fertile from Samoa had a significantly higher
absorbance than the rest of that population (n = 29 A = 2.9,
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n = 134 A = 2.12, respectively; P = 0.016) (Table 1). In both Aus-
tralian and Samoanwomen, the PGP3 ELISA absorbance levels in
women with chlamydial sero-positivity by MIF and who had TFI
or sub-fertility were not significantly different fromwomenwith
current infections (Table 1). However, the PGP3 ELISA absorbance
level was significantly higher in women in Australia with a con-
firmed infection (Group 3, n = 79) compared to all groups except
chlamydial tubal factor infertility (Table 1). Similarly in the par-
ticipants recruited in Samoa, women with a current infection
had high PGP3 ELISA absorbance levels, that were significantly
different from women who were currently infected (mean Abs
3.16, P < 0.0001, n = 86, n = 153). Furthermore, this was also
higher than infected participants in Australia (mean Abs: 2.10,
P < 0.0001) likely due to the higher prevalence of Chlamydia and
lower access to testing and treatment in Samoa.
DISCUSSION
Whilst diagnosis of current chlamydial infections is effective
using NAATs, detection of and population level understanding
of the burden of infection and disease sequelae is not possi-
ble using NAATs. Here, we present an evaluation of the PGP3
ELISA in the Australian and Samoan context comparing chlamy-
dial infertile, fertile and current infection groups. We report that
the PGP3 ELISA absorbance levels were significantly different in
chlamydial infertile or sub-fertile women compared with fer-
tile women in Australia, but only in one fertility clinic setting
and not in another. However, the numbers were small in one
group (n = 5). Additionally, as we used MIF to define Chlamy-
dia infertility, which is reported to have variability in the sensi-
tivity and specificity depending on the reagent preparation and
which have Chlamydia pneumoniae cross-reactivity could mean
some of these participants are mis-assigned (Clad et al. 1994;
Akande et al. 2003). Previously, such cross-reactivity has been
resolved using multiple assays, such as PGP3, but given we are
assessing PGP3 in this context we can only interpret this result
with caution (Ades et al. 2017). There was also significant differ-
ence when comparing chlamydial sub-fertile women in Samoa
with fertile or sub-fertile for other reasons (P = 0.016). However,
in both settings chlamydia infertile or sub-fertile women had
PGP3 ELISA absorbance levels that were not significantly differ-
ent from women with current infections. The groups of women
with current infections in both Samoa and Australia had signifi-
cantly higher absorbance levels than all other groups (apart from
chlamydial infertile) supporting that infectious burden can be
successfully evaluated using this assay in population studies.
One limitation of this study is that we used a single anti-
body dilution and conducted all measures on absorbance levels,
rather than antibody titres. This method is likely to underesti-
mate the differences in serum antibody levels because antibody
responses are not linear. It is important that more work is con-
ducted in high prevalence setting such as Samoa, as our study
is too small to draw conclusions, although the findings support
implementation of the PGP3 ELISA as a sero-epidemiological
tool. AIn neither the higher or lower prevalence groups of
women tested here, did we see a consistent significant differ-
ence in the absorbance betweenwomenwith a current infection
and chlamydial infertility or sub-fertility, and in future serologi-
cal studies using this ELISA it should be considered that positive
result could indicate current or recent infection. However, there
are several studies that report specific, but not sensitive anti-
gens for chlamydial infertility or pathology (e.g. CT117/CT223 for
Ct and cancer; HtrA and OmcB for infertility; HtrA and TroA for
pathology; and CT443 and CT381 for infertility; and 11 different
peptides for infertility), and it could be that a double or multi-
ple antigen approach including PGP3 with these antigens could
be implemented to measure population burdens of chlamydial
infertility (Menon et al. 2016b) (Stansfield et al. 2013) (Rodgers
et al. 2011; Hokynar et al. 2017; Hufnagel et al. 2018; Rahman et al.
2018). Overall, the data presented here add to the evidence that
the PGP3 ELISA could be an effective sero-epidemiological tool
to evaluate the burden of chlamydial infection in women in a
population.
CONCLUSIONS
The data presented here means we now have a global dataset
(in conjunction with the recent UK studies (Horner et al. 2013;
Woodhall et al. 2017)) supporting that the PGP3 ELISA has poten-
tial for sero-epidemiological studies of current and/or past
chlamydial infection of women. We propose the assay could be
used for longitudinal sero-epidemiological monitoring of public
health intervention programs to control and reduce Chlamydia.
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